Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fixed drug eruptions to tetracyclines.

H W Jolly, I J Sherman, C L Carpenter

    Archives of Dermatology
    |October 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Complementary and alternative therapies among very long-term breast cancer survivors.

    Breast cancer research and treatment·2008
    Same author

    Btk-dependent regulation of phosphoinositide synthesis.

    Biochemical Society transactions·2004
    Same author

    Systemic glucocorticosteroid therapy in dermatology.

    Dermatology nursing·2002
    Same author

    Vav2 is required for cell spreading.

    The Journal of cell biology·2001
    Same author

    LKB1 associates with Brg1 and is necessary for Brg1-induced growth arrest.

    The Journal of biological chemistry·2001
    Same author

    Update on systemic glucocorticosteroids in dermatology.

    Dermatologic clinics·2001

    Fixed drug eruptions from tetracyclines were observed in 11 cases. Some patients showed lesion fading despite continued tetracycline use and experienced cross-reactivity to different salts.

    Area of Science:

    • Dermatology
    • Pharmacology

    Background:

    • Fixed drug eruption (FDE) is a specific type of adverse drug reaction.
    • Tetracyclines are a class of antibiotics with potential side effects.

    Observation:

    • Eleven cases of fixed drug eruption attributed to tetracycline use were documented.
    • Two cases involved a familial pattern (mother and adult son).
    • Two patients continued 1g daily dosage with observed lesion fading.

    Findings:

    • Lesion persistence or fading occurred despite continued tetracycline administration in some individuals.
    • Cross-reactivity between different tetracycline salts was noted in several patients.
    • The study highlights variability in FDE presentation and progression.

    Implications:

    Related Experiment Videos

    • Understanding FDE to tetracyclines is crucial for clinical management.
    • Further research into the mechanisms of FDE and cross-reactivity is warranted.
    • This data can inform prescribing practices and patient counseling regarding tetracycline adverse reactions.